Literature DB >> 8583606

Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure.

M Godschalk1, D Gheorghiu, J Chen, P G Katz, T Mulligan.   

Abstract

PURPOSE: We determined the long-term efficacy of intracavernous injection of a new formulation of prostaglandin E1 (Caverject) as treatment for erectile failure.
MATERIALS AND METHODS: A prospective study was done at a university affiliated Veterans Affairs medical center. Subjects with erectile failure received injections of prostaglandin E1 at the office and self-administered injections at home for up to 18 months.
RESULTS: Of 16 patients who performed home injections 15 completed 6 months and 10 completed 18 months of therapy. Patient and spousal satisfaction with intercourse was 90% for months 1 to 6, and patient satisfaction was 95% for months 7 to 18.
CONCLUSIONS: Prostaglandin E1 was highly effective at producing penile rigidity and an erection with satisfactory vaginal intercourse.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8583606

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

Review 1.  Comparative tolerability and efficacy of treatments for impotence.

Authors:  W Meinhardt; R F Kropman; P Vermeij
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

2.  Health-related quality of life in men with erectile dysfunction.

Authors:  M S Litwin; R J Nied; N Dhanani
Journal:  J Gen Intern Med       Date:  1998-03       Impact factor: 5.128

Review 3.  A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.

Authors:  D Vitezic
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.